Clarimedix, Inc. Secures Investment for Proof-of-Concept Study in Cerebral Vasospasm

Clarimedix, Inc. Secures Investment for Proof-of-Concept Study in Cerebral Vasospasm

BOULDER, Colo., Jan. 11, 2012 /PRNewswire/ -- Clarimedix, Inc., a privately held company focused on the development of non-invasive therapeutics for the treatment of disorders associated with vascular dysfunction, today announced that an investment has been secured from the Johnson & Johnson Corporate Office of Science and Technology (COSAT). Financial terms of the deal are not disclosed.

The funds secured from this investment will be used for a human proof-of-concept study to determine the viability of Clarimedix's product for cerebral vasospasm. The study will be completed by the end of the second quarter, at which point the company anticipates closing a further round of investment from an investor syndicate.

"We're delighted to have the investment from the Johnson & Johnson COSAT as we secure validation of Clarimedix's proprietary technology," said John Dunning, CEO of Clarimedix. "Researchers understand there are a wide variety of conditions impacted by underlying vascular dysfunction and our approach may offer the first safe, effective nitric oxide (NO) treatment for patients with these hard-to-treat conditions."

Clarimedix has developed a powerful NO donor alternative with a safety profile that for the first time will enable widespread, safe treatment of a variety of conditions including cerebral vasospasm, Raynaud's phenomenon, and Alzheimer's disease. Clarimedix's technology is a non-invasive, light-based medical device in the form of a light emitting diode (LED) patch that is applied over the skin to trigger local, controllable and safe NO production. As a result, blood flow is increased, vasoconstriction and inflammation are reduced and oxygen delivery to areas that have been deprived improves.

About Clarimedix, Inc:
Clarimedix is a clinical-stage therapeutic device company developing a portfolio of safe, effective therapeutic products that will treat diseases triggered by underlying vascular dysfunction. The company's technology is a nitric oxide (NO) donor therapy that exploits recent developments in our understanding of cellular function and the ability to control it with light. Our unique, patent-pending light 'formulation" triggers a powerful drug-like response, while virtually eliminating the side effects associated with conventional NO donor therapies.

www.tiberendstrategicadvisors.com

Clarimedix, Inc. Contact:
John R. Dunning
Chief Executive Officer
303-905-6163
[email protected]

Media Contact:
Tiberend Strategic Advisors, Inc.
212-827-0020
Andrew Mielach/Stephanie Denis
[email protected] / [email protected]

SOURCE Clarimedix, Inc.
Back to top

RELATED LINKS
http://www.tiberendstrategicadvisors.com

 

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.